Kronox Lab Sciences encumbrance reaches 64.26% after pledge
Key highlights
- CTL Trusteeship’s Kronox Lab Sciences encumbrance rose to 2.38 crore shares, or 64.26%, on November 17, 2026.
- The fresh pledge covered 1.86 crore Kronox Lab Sciences shares, representing 50.26% of equity capital.
- CTL Trusteeship previously reported 0.52 crore Kronox Lab Sciences shares under encumbrance, equal to 14.00%.
- Kronox Lab Sciences’ stated equity capital remained 3.71 crore shares, with face-value capital of Rs 37.104 crore.
powered by IRIS

Kronox Lab Sciences Limited had 2.38 crore shares, representing 64.26% of its equity and voting capital, encumbered with CTL Trusteeship Limited after a 1.86 crore-share pledge created on November 17, 2026. The new pledge alone represented 50.26% of Kronox Lab Sciences’ 3.71 crore equity shares.
Know Kronox Lab Sciences inside out
Results, valuation, peers and who's buying, in one view.
What changed in the Kronox Lab Sciences pledge disclosure?
CTL Trusteeship received a pledge over 1,86,49,440 Kronox Lab Sciences shares on November 17, 2026, equal to 50.26% of the company’s share and voting capital. The filing identifies the mode as creation of a pledge over shares, rather than an open-market purchase, sale, allotment or transfer.
Before the transaction, CTL Trusteeship reported 51,94,560 Kronox Lab Sciences shares under encumbrance, equal to 14.00% of share and voting capital. The fresh pledge increased that position by 1,86,49,440 shares, taking the total to 2,38,44,000 shares, or 64.26%.
The disclosed encumbrance percentage rose by 50.26 percentage points, from 14.00% to 64.26%, because the newly pledged block was larger than the 0.52 crore shares already under encumbrance. The filing records no direct acquisition or sale of Kronox Lab Sciences shares carrying voting rights by CTL Trusteeship.
Who holds security over the Kronox Lab Sciences shares?
CTL Trusteeship holds the disclosed security as trustee on behalf of and for the benefit of Poonawalla Fincorp, which the filing identifies as the lender. CTL Trusteeship is named as the acquirer in the Regulation 29(2) disclosure because it received the security interest over 2,38,44,000 Kronox Lab Sciences shares.
The filing states that CTL Trusteeship is not part of the Kronox Lab Sciences promoter or promoter group. It also shows nil shares carrying voting rights for CTL Trusteeship both before and after November 17, 2026, while the 2.38 crore-share position is recorded solely in the encumbrance category.
CTL Trusteeship’s filing was signed by Additional Director Deesha Srikkanth on November 19, 2026. It was sent to BSE Limited and the National Stock Exchange of India Limited, and cites Regulation 29(2) of the Securities and Exchange Board of India Substantial Acquisition of Shares and Takeovers Regulations, 2011.
How large is the pledged block relative to Kronox Lab Sciences equity?
The post-transaction encumbrance equals 64.26% of Kronox Lab Sciences’ 3,71,04,000 equity shares, or nearly two-thirds of the stated share capital. The newly created pledge of 1,86,49,440 shares accounts for 50.26% of that same capital base.
Kronox Lab Sciences’ equity share capital did not change through the November 17, 2026 pledge. The filing gives both the pre-transaction and post-transaction capital as 3,71,04,000 equity shares with a face value of Rs 10 each, aggregating to Rs 37.104 crore.
Because the equity base remained 3.71 crore shares before and after the event, the rise from 14.00% to 64.26% reflects additional shares being pledged rather than an issue or cancellation of equity. The filing marks total diluted share and voting capital as not applicable, while also recording no warrants, convertible securities or other instruments for CTL Trusteeship.
Got a follow-up? Ask IRIS
What does the filing say about voting rights and ownership?
The filing reports no Kronox Lab Sciences shares carrying voting rights with CTL Trusteeship before or after the November 17, 2026 pledge. Its reported exposure is 51,94,560 encumbered shares before the event and 2,38,44,000 encumbered shares afterwards.
CTL Trusteeship also reported nil voting rights held otherwise than through shares, and nil warrants, convertible securities or other instruments that could entitle it to receive Kronox Lab Sciences shares. The disclosure therefore distinguishes the 64.26% security interest from a reported direct voting-rights holding.
The pledge disclosure does not identify the entity that created the pledge, despite covering 1,86,49,440 shares on November 17, 2026. It also does not disclose the amount financed by Poonawalla Fincorp, the repayment terms, the tenure of the financing or the conditions under which the pledged shares could be invoked.
What information is not provided in the Kronox Lab Sciences filing?
The November 19, 2026 filing provides the share count, percentage and date of the pledge, but not the value of the underlying financing. It identifies Poonawalla Fincorp as lender and CTL Trusteeship as security trustee, without giving the loan amount linked to the 2,38,44,000 encumbered shares.
The disclosure also gives no schedule for a release of the 64.26% encumbrance and no terms for any possible invocation. Its stated equity base of 3,71,04,000 shares was unchanged on November 17, 2026, so the document only establishes the security position reported on that date.
Conclusion
The November 17, 2026 pledge increased CTL Trusteeship’s reported security interest in Kronox Lab Sciences from 0.52 crore shares, or 14.00%, to 2.38 crore shares, or 64.26%. CTL Trusteeship acts for Poonawalla Fincorp, while the filing reports no direct voting-rights shares, warrants or convertible instruments held by the trustee.
The next disclosures to watch are any further pledge creation, release or invocation involving the 2.38 crore Kronox Lab Sciences shares. The filing leaves unresolved the pledgor’s identity, the financing amount, repayment terms and any conditions that could affect the pledged shares.


